FDA plans to publish CAR-T therapeutic product manufacturing guidelines

The development and challenges of "off-the-shelf" allogeneic CAR-T cells Nanjing Cati Medicine July 10
1. Autologous CAR-T cell therapy and allogeneic CAR-T cell therapy
2. Allogeneic CAR-T cell therapy The advantages.Source: From healthy donors, these cells are not affected by the immune effect of cancer, nor are they affected by chemotherapeutic drugs, which are different from the formation of the patient's autologous T cells. Cycle: Compared with autologous CAR-T treatment, allogeneic CAR-T can shorten the treatment cycle and can be prepared in batches

At present, CAR-T cell immunotherapy, as an emerging immunotherapy in recent years, has achieved significant effects in hematological tumors, but the toxic side effects have largely limited the wide application of CAR-T cells, especially cytokine release synthesis. Sign (CRS).